Krascendo 2NCT06793215
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 24 versions: 18 with changes below, 6 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Trial sites expanded: 288 → 299 locations
- Minor Trial sites expanded: 280 → 288 locations
- Eligibility criteria expanded, about 26 words
- Secondary endpoints: details revised at 4 of 9 entries
- Minor Trial sites expanded: 268 → 280 locationsv22
- Minor Trial sites expanded: 260 → 268 locationsv21
- Minor Trial sites expanded: 251 → 260 locationsv20
- Minor Trial sites expanded: 240 → 251 locationsv19
- Minor Trial sites expanded: 217 → 240 locationsv18
- Minor Trial sites expanded: 195 → 217 locationsv17
- Minor Study sites: 180 to 195v16
- Minor Study sites: 151 to 180v15
- Minor Study sites: 105 to 151v14
- Minor Study sites: 63 to 105v13
- Minor Study sites: 32 to 63
- Start date changed from estimate of Dec 1, 2025 to Oct 24, 2025
- Minor Study sites: 10 to 32v11
- Minor Study sites: 6 to 10v10
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 6
- Study completion date: Oct 1, 2030 to Oct 31, 2030
- Notable Primary completion date: Apr 28, 2028 to Nov 30, 2028
- Start date: May 1, 2025 to Dec 1, 2025
- Study completion date: Feb 9, 2030 to Oct 1, 2030
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (9)
Show 4 moreShow less
Arms and interventions
Participants will receive divarasib orally, once daily (QD) and pembrolizumab via intravenous (IV) infusion every 3 weeks (Q3W)
Participants will receive pembrolizumab, pemetrexed and carboplatin or cisplatin via IV infusion Q3W
Drugs: Divarasib, Pembrolizumab, Pemetrexed, Carboplatin, Cisplatin
Sites
299 sites in 28 countries
United States 69, Germany 26, Japan 20, China 19, Italy 16, Spain 15, France 14, United Kingdom 12, Poland 10, Canada 9, Australia 8, Belgium 8, Brazil 7, Greece 7, Netherlands 7, Taiwan 7, South Korea 6, Argentina 5, Denmark 5, Hong Kong 4, Hungary 4, Ireland 4, Portugal 4, Switzerland 4, South Africa 3, Mexico 2, New Zealand 2, Singapore 2